2014

Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Nu Skin Enterprises Inc.

WAYNE, Pa., Jan. 22, 2014 /PRNewswire/ -- Ryan & Maniskas, LLP announces that a class action lawsuit has been filed in the United States District Court for the District of Utah on behalf of purchasers of common stock of Nu Skin Enterprises Inc. ("Nu Skin" or the "Company") (NYSE: NUS) during the period from July 10, 2013 through and including January 14, 2014 (the "Class Period").

(Logo: http://photos.prnewswire.com/prnh/20121112/MM11729LOGO)

If you purchased shares of Nu Skin and would like to learn more about these claims or if you wish to discuss these matters and have any questions concerning this announcement or your rights, contact Richard A. Maniskas, Esquire toll-free at (877) 316-3218 or to sign up online, visit: www.rmclasslaw.com/cases/nus.  You may also email Mr. Maniskas at rmaniskas@rmclasslaw.com.  

Nu Skin develops and distributes anti-aging personal care products and nutritional supplements worldwide under the Nu Skin and Pharmanex brands.

The complaint alleges that during the Class Period, defendants issued a series of false and misleading statements concerning the Company's business practices and growth prospects, particularly with respect to its Mainland China operations, upon which the Company has become very dependent for a very significant amount of its revenue and growth.  Sales in Mainland China accounted for nearly one third of the Company's total revenue in the first nine months of 2013.  Further, the complaint alleges that while the Company issued public statements discussing its positive results and increased guidance, it failed to disclose what are alleged to be fraudulent sales practices and non-compliance with laws and regulations in China, or their potential impact on the Company.  Then, in January 2014, two Chinese agencies announced that they are probing the Company's marketing and business practices in China and that it was suspected the Company was operating as an illegal pyramid scheme.  These revelations had an immediate impact on the Company's stock price, causing shares of Nu Skin's stock, which had risen from less than $70 per share to a high of $140.50 per share during the Class Period, to tumble over 44% in the two days of trading after these announcements.  Nu Skin stock closed the trading day on January 17, 2014 at less than $80 per share.

If you are a member of the class, you may, no later than March 24, 2014, request that the Court appoint you as lead plaintiff of the class.  A lead plaintiff is a representative party that acts on behalf of other class members in directing the litigation.  In order to be appointed lead plaintiff, the Court must determine that the class member's claim is typical of the claims of other class members, and that the class member will adequately represent the class.  Under certain circumstances, one or more class members may together serve as "lead plaintiff."  Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff.  You may retain Ryan & Maniskas, LLP or other counsel of your choice, to serve as your counsel in this action.

Ryan & Maniskas, LLP is a national shareholder litigation firm.  Ryan & Maniskas, LLP is devoted to protecting the interests of individual and institutional investors in shareholder actions in state and federal courts nationwide.  To learn more about the class action process, please visit: www.rmclasslaw.com.

CONTACT:  

Ryan & Maniskas, LLP


Richard A. Maniskas, Esquire


995 Old Eagle School Rd., Suite 311


Wayne, PA 19087


484-588-5516


877-316-3218


www.rmclasslaw.com/cases/nus    


rmaniskas@rmclasslaw.com

SOURCE Ryan & Maniskas, LLP



RELATED LINKS
http://www.rmclasslaw.com

More by this Source


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.